Logo image of CATX

PERSPECTIVE THERAPEUTICS INC (CATX) Stock Fundamental Analysis

NYSEARCA:CATX - NYSE Arca - US46489V3024 - Common Stock - Currency: USD

3.68  +0.05 (+1.38%)

After market: 3.6101 -0.07 (-1.9%)

Fundamental Rating

2

CATX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 550 industry peers in the Biotechnology industry. While CATX seems to be doing ok healthwise, there are quite some concerns on its profitability. CATX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CATX had negative earnings in the past year.
CATX had a negative operating cash flow in the past year.
CATX had negative earnings in each of the past 5 years.
CATX had a negative operating cash flow in each of the past 5 years.
CATX Yearly Net Income VS EBIT VS OCF VS FCFCATX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

CATX's Return On Assets of -25.86% is fine compared to the rest of the industry. CATX outperforms 71.51% of its industry peers.
CATX's Return On Equity of -29.92% is fine compared to the rest of the industry. CATX outperforms 77.31% of its industry peers.
Industry RankSector Rank
ROA -25.86%
ROE -29.92%
ROIC N/A
ROA(3y)-27.34%
ROA(5y)-25.32%
ROE(3y)-33.67%
ROE(5y)-33.3%
ROIC(3y)N/A
ROIC(5y)N/A
CATX Yearly ROA, ROE, ROICCATX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

CATX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CATX Yearly Profit, Operating, Gross MarginsCATX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

5

2. Health

2.1 Basic Checks

CATX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CATX has more shares outstanding
CATX has more shares outstanding than it did 5 years ago.
CATX has a better debt/assets ratio than last year.
CATX Yearly Shares OutstandingCATX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
CATX Yearly Total Debt VS Total AssetsCATX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

CATX has an Altman-Z score of 2.59. This is not the best score and indicates that CATX is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.59, CATX is in the better half of the industry, outperforming 70.78% of the companies in the same industry.
A Debt/Equity ratio of 0.01 indicates that CATX is not too dependend on debt financing.
CATX's Debt to Equity ratio of 0.01 is in line compared to the rest of the industry. CATX outperforms 43.92% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 2.59
ROIC/WACCN/A
WACC9.76%
CATX Yearly LT Debt VS Equity VS FCFCATX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 17.02 indicates that CATX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 17.02, CATX belongs to the top of the industry, outperforming 90.93% of the companies in the same industry.
A Quick Ratio of 17.02 indicates that CATX has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 17.02, CATX belongs to the best of the industry, outperforming 91.11% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 17.02
Quick Ratio 17.02
CATX Yearly Current Assets VS Current LiabilitesCATX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

3

3. Growth

3.1 Past

CATX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 40.67%, which is quite impressive.
The Revenue for CATX has decreased by -75.62% in the past year. This is quite bad
Measured over the past years, CATX shows a very negative growth in Revenue. The Revenue has been decreasing by -27.60% on average per year.
EPS 1Y (TTM)40.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
Revenue 1Y (TTM)-75.62%
Revenue growth 3Y-47.5%
Revenue growth 5Y-27.6%
Sales Q2Q%5.23%

3.2 Future

CATX is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -7.64% yearly.
The Revenue is expected to grow by 173.29% on average over the next years. This is a very strong growth
EPS Next Y-55.15%
EPS Next 2Y-33.42%
EPS Next 3Y-23.93%
EPS Next 5Y-7.64%
Revenue Next Year-40.4%
Revenue Next 2Y-18.3%
Revenue Next 3Y-4.57%
Revenue Next 5Y173.29%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CATX Yearly Revenue VS EstimatesCATX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M 500M
CATX Yearly EPS VS EstimatesCATX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 0.5 -0.5 1 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CATX. In the last year negative earnings were reported.
Also next year CATX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CATX Price Earnings VS Forward Price EarningsCATX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CATX Per share dataCATX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

A cheap valuation may be justified as CATX's earnings are expected to decrease with -23.93% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-33.42%
EPS Next 3Y-23.93%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CATX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PERSPECTIVE THERAPEUTICS INC

NYSEARCA:CATX (8/8/2025, 8:22:30 PM)

After market: 3.6101 -0.07 (-1.9%)

3.68

+0.05 (+1.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)08-13 2025-08-13/bmo
Inst Owners61.15%
Inst Owner Change0.38%
Ins Owners3.07%
Ins Owner Change0.1%
Market Cap273.17M
Analysts81.05
Price Target13.89 (277.45%)
Short Float %10.54%
Short Ratio4.81
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.11%
Min EPS beat(2)7.98%
Max EPS beat(2)20.23%
EPS beat(4)4
Avg EPS beat(4)11.92%
Min EPS beat(4)3.49%
Max EPS beat(4)20.23%
EPS beat(8)6
Avg EPS beat(8)-20.72%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)63.16%
Min Revenue beat(2)-6.05%
Max Revenue beat(2)132.36%
Revenue beat(4)3
Avg Revenue beat(4)97.07%
Min Revenue beat(4)-6.05%
Max Revenue beat(4)225.01%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.72%
PT rev (3m)-2.21%
EPS NQ rev (1m)0%
EPS NQ rev (3m)7.26%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)25.27%
Revenue NY rev (1m)20.13%
Revenue NY rev (3m)20.13%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 185.7
P/FCF N/A
P/OCF N/A
P/B 0.96
P/tB 1.16
EV/EBITDA N/A
EPS(TTM)-0.89
EYN/A
EPS(NY)-1.5
Fwd EYN/A
FCF(TTM)-1.4
FCFYN/A
OCF(TTM)-0.72
OCFYN/A
SpS0.02
BVpS3.83
TBVpS3.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.86%
ROE -29.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.34%
ROA(5y)-25.32%
ROE(3y)-33.67%
ROE(5y)-33.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1867.23%
Cap/Sales 3404.42%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17.02
Quick Ratio 17.02
Altman-Z 2.59
F-Score4
WACC9.76%
ROIC/WACCN/A
Cap/Depr(3y)856.63%
Cap/Depr(5y)587.66%
Cap/Sales(3y)1275.31%
Cap/Sales(5y)766.6%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
EPS Next Y-55.15%
EPS Next 2Y-33.42%
EPS Next 3Y-23.93%
EPS Next 5Y-7.64%
Revenue 1Y (TTM)-75.62%
Revenue growth 3Y-47.5%
Revenue growth 5Y-27.6%
Sales Q2Q%5.23%
Revenue Next Year-40.4%
Revenue Next 2Y-18.3%
Revenue Next 3Y-4.57%
Revenue Next 5Y173.29%
EBIT growth 1Y0.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-37.89%
EBIT Next 3Y-20.9%
EBIT Next 5YN/A
FCF growth 1Y-828.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-388.84%
OCF growth 3YN/A
OCF growth 5YN/A